secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0000950170-22-010081
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics appoints Phuong Khanh Morrow, M.D., as Chief Medical Officer effective May 23, 2022
--------------------------------------------------------------------------------

- Dr. Morrow brings over a decade of global drug development experience, most recently as VP at Amgen leading hematology/oncology.
- She will lead CRISPR Therapeutics' global clinical development and regulatory operations.
- CEO Samarth Kulkarni cited her expertise in oncology and track record in bringing novel medicines to patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017022010081/0000950170-22-010081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017022010081/crsp-20220516.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-010081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer